- Pharmaceutical industry
The pharmaceutical industry develops, produces, and markets drugs licensed for use as medications. Pharmaceutical companies are allowed to deal in generic and/or brand medications and medical devices. They are subject to a variety of laws and regulations regarding the patenting, testing and ensuring safety and efficacy and marketing of drugs.
The earliest drugstores date back to the Middle Ages. The first known drugstore was opened by Arabian pharmacists in Baghdad in 754, and many more soon began operating throughout the medieval Islamic world and eventually medieval Europe. By the 19th century, many of the drugstores in Europe and North America had eventually developed into larger pharmaceutical companies.
Most of today's major pharmaceutical companies were founded in the late 19th and early 20th centuries. Key discoveries of the 1920s and 1930s, such as insulin and penicillin, became mass-manufactured and distributed. Switzerland, Germany and Italy had particularly strong industries, with the UK, US, Belgium and the Netherlands following suit.
Legislation was enacted to test and approve drugs and to require appropriate labeling. Prescription and non-prescription drugs became legally distinguished from one another as the pharmaceutical industry matured. The industry got underway in earnest from the 1950s, due to the development of systematic scientific approaches, understanding of human biology (including DNA) and sophisticated manufacturing techniques.
Numerous new drugs were developed during the 1950s and mass-produced and marketed through the 1960s. These included the first oral contraceptive, "The Pill", Cortisone, blood-pressure drugs and other heart medications. MAO Inhibitors, chlorpromazine (Thorazine), Haldol (Haloperidol) and the tranquilizers ushered in the age of psychiatric medication. Valium (diazepam), discovered in 1960, was marketed from 1963 and rapidly became the most prescribed drug in history, prior to controversy over dependency and habituation.
Attempts were made to increase regulation and to limit financial links between companies and prescribing physicians, including by the relatively new U.S. Food and Drug Administration (FDA). Such calls increased in the 1960s after the thalidomide tragedy came to light, in which the use of a new tranquilizer in pregnant women caused severe birth defects. In 1964, the World Medical Association issued its Declaration of Helsinki, which set standards for clinical research and demanded that subjects give their informed consent before enrolling in an experiment. Pharmaceutical companies became required to prove efficacy in clinical trials before marketing drugs.
The industry remained relatively small scale until the 1970s when it began to expand at a greater rate. Legislation allowing for strong patents, to cover both the process of manufacture and the specific products, came in to force in most countries. By the mid-1980s, small biotechnology firms were struggling for survival, which led to the formation of mutually beneficial partnerships with large pharmaceutical companies and a host of corporate buyouts of the smaller firms. Pharmaceutical manufacturing became concentrated, with a few large companies holding a dominant position throughout the world and with a few companies producing medicines within each country.
The pharmaceutical industry entered the 1980s pressured by economics and a host of new regulations, both safety and environmental, but also transformed by new DNA chemistries and new technologies for analysis and computation. Drugs for heart disease and for AIDS were a feature of the 1980s, involving challenges to regulatory bodies and a faster approval process.
Managed care and Health maintenance organizations (HMOs) spread during the 1980s as part of an effort to contain rising medical costs, and the development of preventative and maintenance medications became more important. A new business atmosphere became institutionalized in the 1990s, characterized by mergers and takeovers, and by a dramatic increase in the use of contract research organizations for clinical development and even for basic R&D. The pharmaceutical industry confronted a new business climate and new regulations, born in part from dealing with world market forces and protests by activists in developing countries. Animal Rights activism was also a challenge.
Marketing changed dramatically in the 1990s, partly because of a new consumerism. The Internet made possible the direct purchase of medicines by drug consumers and of raw materials by drug producers, transforming the nature of business. In the US, Direct-to-consumer advertising proliferated on radio and TV because of new FDA regulations in 1997 that liberalized requirements for the presentation of risks. The new antidepressants, the SSRIs, notably Fluoxetine (Prozac), rapidly became bestsellers and marketed for additional disorders.
Drug development progressed from a hit-and-miss approach to rational drug discovery in both laboratory design and natural-product surveys. Demand for nutritional supplements and so-called alternative medicines created new opportunities and increased competition in the industry. Controversies emerged around adverse effects, notably regarding Vioxx in the US, and marketing tactics. Pharmaceutical companies became increasingly accused of disease mongering or over-medicalizing personal or social problems.
Research and development
Drug discovery is the process by which potential drugs are discovered or designed. In the past most drugs have been discovered either by isolating the active ingredient from traditional remedies or by serendipitous discovery. Modern biotechnology often focuses on understanding the metabolic pathways related to a disease state or pathogen, and manipulating these pathways using molecular biology or biochemistry. A great deal of early-stage drug discovery has traditionally been carried out by universities and research institutions.
Drug development refers to activities undertaken after a compound is identified as a potential drug in order to establish its suitability as a medication. Objectives of drug development are to determine appropriate Formulation and Dosing, as well as to establish safety. Research in these areas generally includes a combination of in vitro studies, in vivo studies, and clinical trials. The amount of capital required for late stage development has made it a historical strength of the larger pharmaceutical companies. Suggested citation: Tufts Center for the Study of Drug Development, Annual Impact Report, http://csdd.tufts.edu/
Often, large multinational corporations exhibit vertical integration, participating in a broad range of drug discovery and development, manufacturing and quality control, marketing, sales, and distribution. Smaller organizations, on the other hand, often focus on a specific aspect such as discovering drug candidates or developing formulations. Often, collaborative agreements between research organizations and large pharmaceutical companies are formed to explore the potential of new drug substances.
The cost of innovation
Drug companies are like other companies in that they manufacture products that must be sold for a profit in order for the company to survive and grow. They are different from some companies because the drug business is very risky. For instance, only one out of every ten thousand discovered compounds actually becomes an approved drug for sale. Much expense is incurred in the early phases of development of compounds that will not become approved drugs. In addition, it takes about 7 to 10 years and only 3 out of every 20 approved drugs bring in sufficient revenue to cover their developmental costs, and only 1 out of every 3 approved drugs generates enough money to cover the development costs of previous failures. This means that for a drug company to survive, it needs to discover a blockbuster (billion-dollar drug) every few years.
Drug discovery and development is very expensive; of all compounds investigated for use in humans only a small fraction are eventually approved in most nations by government appointed medical institutions or boards, who have to approve new drugs before they can be marketed in those countries. In 2010 18 NMEs (New Molecular Entities)were approved and three biologics by the FDA, or 21 in total, which is down from 26 in 2009 and 24 in 2008. On the other hand, there were only 18 approvals in total in 2007 and 22 back in 2006. Since 2001, the Center for Drug Evaluation and Research has averaged 22.9 approvals a year. This approval comes only after heavy investment in pre-clinical development and clinical trials, as well as a commitment to ongoing safety monitoring. Drugs which fail part-way through this process often incur large costs, while generating no revenue in return. If the cost of these failed drugs is taken into account, the cost of developing a successful new drug (New chemical entity or NCE), has been estimated at about 1.3 billion USD(not including marketing expenses).
Industry-wide research and investment reached a record $65.3 billion in 2009.
A study by the consulting firm Bain & Company reported that the cost for discovering, developing and launching (which factored in marketing and other business expenses) a new drug (along with the prospective drugs that fail) rose over a five year period to nearly $1.7 billion in 2003.
These estimates also take into account the opportunity cost of investing capital many years before revenues are realized (see Time-value of money). Because of the very long time needed for discovery, development, and approval of pharmaceuticals, these costs can accumulate to nearly half the total expense. Some approved drugs, such as those based on re-formulation of an existing active ingredient (also referred to as Line-extensions) are much less expensive to develop.
Calculations and claims in this area are controversial because of the implications for regulation and subsidization of the industry through tax credits and federally funded research grants.
Competition between pharmaceutical companies has resulted in "me-too" drugs, which are defined as chemically-similar compounds or compounds with the same mechanism of action as an existing, approved chemical entity. According to an FDA report in 2004, there were 941 new drug and biologics license application approvals between 1995 and 2004, of which only 311 were "new" biologics or New Molecular Entities, defined by the FDA as “containing an active substance that has never before been approved for marketing in any form in the United States”.
Critics of the pharma industry point out that "me-too" drugs are only brought to market because their development is cheaper and less risky. However proponents point to the cost benefits of market competition between similar drugs. It may take 10 or more years for a drug to go from discovery to FDA Approval, and if a new clinical pathway is discovered, multiple companies often will research a compound to treat within this pathway leading to several similar or "me-too" drugs to arrive in what seems to be nearly at the same time. This is why some suggest that much of the “me-too” drug phenomenon is a result of parallel research at rival companies.
Controversy about drug development and testing
Due to accusations and findings that some clinical trials conducted or funded by pharmaceutical companies may report only positive results for the preferred medication, the industry has been looked at much more closely by independent groups and government agencies.
In response to specific cases in which unfavorable data from pharmaceutical company-sponsored research was not published, the Pharmaceutical Research and Manufacturers of America have published new guidelines urging companies to report all findings and limit the financial involvement in drug companies of researchers. US congress signed into law a bill which requires phase II and phase III clinical trials to be registered by the sponsor on the clinical trials.gov website run by the NIH.
Drug researchers not directly employed by pharmaceutical companies often look to companies for grants, and companies often look to researchers for studies that will make their products look favorable. Sponsored researchers are rewarded by drug companies, for example with support for their conference/symposium costs. Lecture scripts and even journal articles presented by academic researchers may actually be 'ghost-written' by pharmaceutical companies. Some researchers who have tried to reveal ethical issues with clinical trials or who tried to publish papers that show harmful effects of new drugs or cheaper alternatives have been threatened by drug companies with lawsuits.
Product approval in the US
In the United States, new pharmaceutical products must be approved by the Food and Drug Administration (FDA) as being both safe and effective. This process generally involves submission of an Investigational new drug filing with sufficient pre-clinical data to support proceeding with human trials. Following IND approval, three phases of progressively larger human clinical trials may be conducted. Phase I generally studies toxicity using healthy volunteers. Phase II can include Pharmacokinetics and Dosing in patients, and Phase III is a very large study of efficacy in the intended patient population. Following the successful completion of phase III testing, a New Drug Application is submitted to the FDA. The FDA review the data and if the product is seen as having a positive benefit-risk assessment, approval to market the product in the US is granted.
A fourth phase of post-approval surveillance is also often required due to the fact that even the largest clinical trials cannot effectively predict the prevalence of rare side-effects. Post-marketing surveillance ensures that after marketing the safety of a drug is monitored closely. In certain instances, its indication may need to be limited to particular patient groups, and in others the substance is withdrawn from the market completely. Questions continue to be raised regarding the standard of both the initial approval process, and subsequent changes to product labeling (it may take many months for a change identified in post-approval surveillance to be reflected in product labeling) and this is an area where congress is active.
The FDA provides information about approved drugs at the Orange Book site.
There are special rules for certain rare diseases ("orphan diseases") involving fewer than 200,000 patients in the United States, or larger populations in certain circumstances.  Because medical research and development of drugs to treat such diseases is financially disadvantageous, companies that do so are rewarded with tax reductions, fee waivers, and market exclusivity on that drug for a limited time (seven years), regardless of whether the drug is protected by patents.
Where pharmaceutics have been shown to cause side-effects, civil action has occurred, especially in countries where tort payouts are likely to be large. Due to high-profile cases leading to large compensations, most pharmaceutical companies endorse tort reform. Recent controversies have involved Vioxx and SSRI antidepressants.
Product approval elsewhere
In many non-US western countries a 'fourth hurdle' of cost effectiveness analysis has developed before new technologies can be provided. This focuses on the efficiency (in terms of the cost per QALY) of the technologies in question rather than their efficacy. In England NICE approval requires technologies be made available by the NHS, whilst similar arrangements exist with the Scottish Medicines Consortium in Scotland and the Pharmaceutical Benefits Advisory Committee in Australia. A product must pass the threshold for cost-effectiveness if it is to be approved. Treatments must represent 'value for money' and a net benefit to society. There is much speculation that a NICE style framework may be implemented in the USA to ensure Medicare and Medicaid spending is focused to maximize benefit to patients and not excessive profits for the pharmaceutical industry.
In the UK, the British National Formulary is the core guide for pharmacists and clinicians.
For the first time ever, in 2006, global spending on prescription drugs topped $643 billion, even as growth slowed somewhat in Europe and North America. The United States accounts for almost half of the global pharmaceutical market, with $289 billion in annual sales followed by the EU and Japan.(pdf) Emerging markets such as China, Russia, South Korea and Mexico outpaced that market, growing a huge 81 percent.
US profit growth was maintained even whilst other top industries saw little or no growth. Despite this, "..the pharmaceutical industry is — and has been for years — the most profitable of all businesses in the U.S. In the annual Fortune 500 survey, the pharmaceutical industry topped the list of the most profitable industries, with a return of 17% on revenue."
Pfizer's cholesterol pill Lipitor remains a best-selling drug world wide. Its annual sales were $12.9 billion, more than twice as much as its closest competitors: Plavix, the blood thinner from Bristol-Myers Squibb and Sanofi-Aventis; Nexium, the heartburn pill from AstraZeneca; and Advair, the asthma inhaler from GlaxoSmithKline.
IMS Health publishes an analysis of trends expected in the pharmaceutical industry in 2007, including increasing profits in most sectors despite loss of some patents, and new 'blockbuster' drugs on the horizon.
Teradata Magazine predicted that by 2007, $40 billion in U.S. sales could be lost at the top 10 pharmaceutical companies as a result of slowdown in R&D innovation and the expiry of patents on major products, with 19 blockbuster drugs losing patent.
Market leaders in terms of revenue
The following is a list of the 20 largest pharmaceutical and biotech companies ranked by healthcare revenue. Some companies (e.g., Bayer, Johnson and Johnson and Procter & Gamble) have additional revenue not included here. The phrase Big Pharma is often used to refer to companies with revenue in excess of $3 billion, and/or R&D expenditure in excess of $500 million.
Revenue Rank 2008 Company Country Total Revenues (USD millions) Healthcare R&D 2006 (USD millions) Net income/ (loss) 2006 (USD millions) Employees 2006 1 Pfizer USA 67,809 7,599 19,337 122,200 2 Novartis Switzerland 53,324 7,125 11,053 138,000 3 Merck & Co. USA 45,987 4,783 4,434 74,372 4 Bayer Germany 44,200 1,791 6,450 106,200 5 GlaxoSmithKline United Kingdom 42,813 6,373 10,135 106,000 6 Johnson and Johnson USA 37,020 5,349 7,202 102,695 7 Sanofi France 35,645 5,565 5,033 100,735 8 Hoffmann–La Roche Switzerland 33,547 5,258 7,318 100,289 9 AstraZeneca United Kingdom 26,475 3,902 6,063 50,000+ 10 Abbott Laboratories USA 22,476 2,255 1,717 66,800 11 Bristol-Myers Squibb USA 17,914 3,067 1,585 60,000 12 Eli Lilly and Company USA 15,691 3,129 2,663 50,060 13 Amgen USA 14,268 3,366 2,950 48,000 14 Boehringer Ingelheim Germany 13,284 1,977 2,163 43,000 15 Schering-Plough USA 10,594 2,188 1,057 41,500 16 Baxter International USA 10,378 614 1,397 38,428 17 Takeda Pharmaceutical Co. Japan 10,284 1,620 2,870 15,000 18 Genentech USA 9,284 1,773 2,113 33,500 19 Procter & Gamble USA 8,964 n/a 10,340 29,258 SUM 497,519 70,843 110,077 1,342,700 AVERAGE 24876 3542 5504 67135
Market leaders in terms of sales
Rank Company Sales ($M) Based/Headquartered in 1 Pfizer 43,363 US 2 GlaxoSmithKline 36,506 United Kingdom 3 Novartis 36,506 Switzerland 4 Sanofi-Aventis 35,642 France 5 AstraZeneca 32,516 United Kingdom 6 Hoffmann–La Roche 30,336 Switzerland 7 Johnson & Johnson 29,425 US 8 Merck & Co. 26,191 US 9 Abbott 19,466 US 10 Eli Lilly and Company 19,140 US 11 Amgen 15,794 US 12 Wyeth 15,682 US 13 Teva 15,274 Israel 14 Bayer 15,660 Germany 15 Takeda 13,819 Japan
Patents and generics
Depending on a number of considerations, a company may apply for and be granted a patent for the drug, or the process of producing the drug, granting exclusivity rights typically for about 20 years. However, only after rigorous study and testing, which takes 10 to 15 years on average, will governmental authorities grant permission for the company to market and sell the drug. Patent protection enables the owner of the patent to recover the costs of research and development through high profit margins for the branded drug. When the patent protection for the drug expires, a generic drug is usually developed and sold by a competing company. The development and approval of generics is less expensive, allowing them to be sold at a lower price. Often the owner of the branded drug will introduce a generic version before the patent expires in order to get a head start in the generic market. Restructuring has therefore become routine, driven by the patent expiration of products launched during the industry's 'golden era' in the 1990s and companies' failure to develop sufficient new blockbuster products to replace lost revenues.
Medicare Part D
In 2003 the United States enacted the Medicare Prescription Drug, Improvement, and Modernization Act (MMA), a program to provide prescription drug benefits to the elderly and disabled. This program is a component of Medicare (United States) and is known as Medicare Part D. This program, set to begin in January 2006, will significantly alter the revenue models for pharmaceutical companies. Revenues from the program are expected to be $724 billion between 2006 and 2015.
Pharmaceuticals developed by biotechnological processes often must be injected in a physician's office rather than be delivered in the form of a capsule taken orally. Medicare payments for these drugs are usually made through Medicare Part B (physician office) rather than Part D (prescription drug plan).
Mergers, acquisitions, and co-marketing of drugs
A merger, acquisition, or co-marketing deal between pharmaceutical companies may occur as a result of complementary capabilities between them. A small biotechnology company might have a new drug but no sales or marketing capability. Conversely, a large pharmaceutical company might have unused capacity in a large sales force due to a gap in the company pipeline of new products. It may be in both companies' interest to enter into a deal to capitalize on the synergy between the companies.
In the U.S., prescriptions have increased over the past decade to 3.4 billion annually, a 61 percent increase. Retail sales of prescription drugs jumped 250 percent from $72 billion to $250 billion, while the average price of prescriptions has more than doubled from $30 to $68.
Pharmaceutical companies commonly spend a large amount on advertising, marketing and lobbying. In the US, drug companies spend $19 billion a year on promotions. Advertising is common in healthcare journals as well as through more mainstream media routes. In some countries, notably the US, they are allowed to advertise directly to the general public. Pharmaceutical companies generally employ sales people (often called 'drug reps' or, an older term, 'detail men') to market directly and personally to physicians and other healthcare providers. In some countries, notably the US, pharmaceutical companies also employ lobbyists to influence politicians. Marketing of prescription drugs in the US is regulated by the federal Prescription Drug Marketing Act of 1987.
To healthcare professionals
Currently, there are approximately 81,000 pharmaceutical sales reps in the United States pursuing some 830,000 pharmaceutical prescribers. A pharmaceutical representative will often try to see a given physician every few weeks. Representatives often have a call list of about 200-300 physicians with 120-180 targets that should be visited in 1-2 or 3 week cycle. The number of pharmaceutical sales reps has been shrinking between 2008 and 2010, an estimated 30% industry wide reduction has occurred and current estimates are there may only be 60,000 pharmaceutical sales reps in the United States.
To insurance and public health bodies
Private insurance or public health bodies (e.g. the NHS in the UK) decide which drugs to pay for, and restrict the drugs that can be prescribed through the use of formularies. Public and private insurers restrict the brands, types and number of drugs that they will cover. Not only can the insurer affect drug sales by including or excluding a particular drug from a formulary, they can affect sales by tiering or placing bureaucratic hurdles to prescribing certain drugs as well. In January 2006, the U.S. instituted a new public prescription drug plan through its Medicare program known as Medicare Part D. This program engages private insurers to negotiate with pharmaceutical companies for the placement of drugs on tiered formularies.
To retail pharmacies and stores
Commercial stores and pharmacies are a major target of non-prescription sales and marketing for pharmaceutical companies.
Direct to consumer advertising
Since the 1980s new methods of marketing for prescription drugs to consumers have become important. Direct-to-consumer media advertising was legalised in the FDA Guidance for Industry on Consumer-Directed Broadcast Advertisements.
Internationally, many pharmaceutical companies market directly to the consumer rather than going through a conventional retail sales channel. For example, Japan-based Kenrico markets largely though its company website.
Controversy about drug marketing and lobbying
There has been increasing controversy surrounding pharmaceutical marketing and influence. There have been accusations and findings of influence on doctors and other health professionals through drug reps, including the constant provision of marketing 'gifts' and biased information to health professionals; highly prevalent advertising in journals and conferences; funding independent healthcare organizations and health promotion campaigns; lobbying physicians and politicians (more than any other industry in the US); sponsorship of medical schools or nurse training; sponsorship of continuing educational events, with influence on the curriculum; and hiring physicians as paid consultants on medical advisory boards.
To help ensure the status quo on U.S. drug regulation and pricing, the pharmaceutical industry has thousands of lobbyists in Washington, DC that lobby Congress and protect their interests. The pharmaceutical industry spent $855 million, more than any other industry, on lobbying activities from 1998 to 2006, according to the non-partisan Center for Public Integrity.
Some advocacy groups, such as No Free Lunch, have criticized the effect of drug marketing to physicians because they say it biases physicians to prescribe the marketed drugs even when others might be cheaper or better for the patient.
There have been related accusations of disease mongering (over-medicalising) to expand the market for medications. An inaugural conference on that subject took place in Australia in 2006. In 2009, the Government-funded National Prescribing Service launched the "Finding Evidence - Recognising Hype" program, aimed at educating GPs on methods for independent drug analysis.
A 2005 review by a special committee of the UK government came to all the above conclusions in a European Union context whilst also highlighting the contributions and needs of the industry.
There is also huge concern about the influence of the pharmaceutical industry on the scientific process. Meta-analyses have shown that studies sponsored by pharmaceutical companies are several times more likely to report positive results, and if a drug company employee is involved (as is often the case, often multiple employees as co-authors and helped by contracted marketing companies) the effect is even larger. Influence has also extended to the training of doctors and nurses in medical schools, which is being fought.
It has been argued that the design of the Diagnostic and Statistical Manual of Mental Disorders and the expansion of the criteria represents an increasing medicalization of human nature, or "disease mongering", driven by drug company influence on psychiatry. The potential for direct conflict of interest has been raised, partly because roughly half the authors who selected and defined the DSM-IV psychiatric disorders had or previously had financial relationships with the pharmaceutical industry. The president of the organization that designs and publishes the DSM, the American Psychiatric Association, recently acknowledged that in general American psychiatry has "allowed the biopsychosocial model to become the bio-bio-bio model" and routinely accepted "kickbacks and bribes" from pharmaceutical companies.
The role of pharmaceutical companies in the developing world is a matter of some debate, ranging from those highlighting the aid provided to the developing world, to those critical of the use of the poorest in human clinical trials, often without adequate protections, particularly in states lacking a strong rule of law. Other criticisms include an alleged reluctance of the industry to invest in treatments of diseases in less economically advanced countries, such as malaria; Criticism for the price of patented AIDS medication, which could limit therapeutic options for patients in the Third World, where most of the AIDS infected people are living.
In September 2008 the Open Source Drug Discovery Network was launched in India to combat infectious diseases common to developing countries.
Patents have been criticized in the developing world, as they are thought to reduce access to medicines. However, under the TRIPS agreement of the World Trade Organization, countries must allow pharmaceutical products to be patented. In 2001, the WTO adopted the Doha Declaration, which indicates that the TRIPS agreement should be read with the goals of public health in mind, and allows some methods for circumventing pharmaceutical monopolies: via compulsory licensing or parallel imports, even before patent expiration.
In March 2001, 40 multi-national pharmaceutical companies brought litigation against South Africa for its Medicines Act, which allowed the generic production of antiretroviral drugs (ARVs) for treating HIV, despite the fact that these drugs were on-patent. HIV was and is an epidemic in South Africa, and ARVs at the time cost between 10,000 and 15,000 USD per patient per year. This was unaffordable for most South African citizens, and so the South African government committed to providing ARVs at prices closer to what people could afford. To do so, they would need to ignore the patents on drugs and produce generics within the country (using a compulsory license), or import them from abroad. The Indian pharmaceutical company Cipla audaciously offered to make the drugs at 350 USD per patient per year, roughly 1/40th of the lowest price available from a patent holder, which stunned the world community. After massive international protest in favour of public health rights (including the collection of 250,000 signatures by MSF), the governments of several developed countries (including The Netherlands, Germany, France, and later the US) backed the South African government, and the case was dropped in April of that year.
Nigerian clinical trial
Charitable programs and drug discovery & development efforts are routinely undertaken by pharmaceutical companies. Some examples include:
- "Merck's Gift," wherein billions of River Blindness drugs were donated in Africa 
- Pfizer's gift of free/discounted fluconazole and other drugs for AIDS in South Africa 
- GSK's commitment to give free albendazole tablets to the WHO for, and until, the elimination of lymphatic filariasis worldwide.
- In 2006, Novartis committed USD 755 million in corporate citizenship initiatives around the world, particularly focusing on improved access to medicines in the developing world through its Access to Medicine projects, including donations of medicines to patients affected by leprosy, tuberculosis, and malaria; Glivec patient assistance programmes; and relief to support major humanitarian organisations with emergency medical needs.
However, some NGOs such as Médecins Sans Frontières do not routinely accept corporate donations of medicines. More precisely, they do not become reliant on such supplies of medicines because the supply is dependent upon the fluid, profit-driven charities of said pharmaceutical companies, and thus may dry up during a critical or otherwise important time. The book An Imperfect Offering: Humanitarian Action for the 21st Century by ex-MSF president James Orbinski describes this in detail.
Pharmaceutical industry in popular culture
As for many other major industries since the middle of the twentieth century, the pharmaceutical industry has been portrayed as a global shadowy force in numerous western fiction works. Notorious films such as The Fugitive (1993) and Resident evil and novels/films such as The Constant Gardener characterize this trend.
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE)
- Drug Information Association (DIA)
- European Federation of Pharmaceutical Industries and Associations (EFPIA)
- European Pharmaceutical Market Research Association (EphMRA)
- International Federation of Pharmaceutical Manufacturers and Associations (IFPMA)
- Japan Pharmaceutical Manufacturers Association (JPMA)
- New York Health Products Council (NYHPC)
- Pharmaceutical Research and Manufacturers of America (PhRMA)
- Irish Pharmaceutical Healthcare Association (IPHA)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH)
- European Medicines Agency (EMEA)
- Therapeutic Goods Administration (Australia) (TGA)
- U.S. Food and Drug Administration (FDA)
- Ministry of Health, Labour and Welfare (Japan)
- Medicines and Healthcare products Regulatory Agency (MHRA)
- Central Drugs Standards Control Organisation (India) (CDSCO)
- Ukrainian Drug Registration Agency
- Medicines Authority (Malta)
- Clinical trial
- Drug development
- Drug design
- Drug discovery
- Inverse benefit law
- List of pharmaceutical companies
- Pharmaceutical marketing
- ^ John L. McGuire, Horst Hasskarl, Gerd Bode, Ingrid Klingmann, Manuel Zahn "Pharmaceuticals, General Survey" Ullmann's Encyclopedia of Chemical Technology" Wiley-VCH, Weinheim, 2007. doi:10.1002/14356007.a19_273.pub2
- ^ Information taken from the abstract of Hadzović, S (1997). "Pharmacy and the great contribution of Arab-Islamic science to its development" (in Croatian). Medicinski arhiv 51 (1–2): 47–50. ISSN 0350-199X. OCLC 32564530. PMID 9324574.
- ^ http://www.dklevine.com/papers/ip.ch.9.m1004.pdf
- ^ a b Ray Moynihan and Alan Cassels (2005). Selling Sickness: How Drug Companies are Turning Us All Into Patients. Allen & Unwin. New York. ISBN 1-74114-579-1
- ^ a b "Why Drugs Cost So Much". Medicine.net. http://www.medicinenet.com/script/main/art.asp?articlekey=18892.
- ^ "How Many New Drugs Did FDA Approve Last Year?". pharmalot.com. http://www.pharmalot.com/2011/02/how-many-new-drugs-did-fda-approve-last-year/.
- ^ Tufts Center for the Study of Drug Development
- ^ a b c The Pharmaceutical Research and Manufacturers of America (PhRMA
- ^ Sheila Campbell, et al (June 2007). "Federal Support for Research and Development". Congressional Budget Office. http://www.cbo.gov/doc.cfm?index=8221&type=0.
- ^ Garattini, S. (1997). "Are me-too drugs justificed?". Journal of Nephrology 10 (6): 283–294. PMID 9442441
- ^ "CDER 2004 Report to the Nation: Improving Public Health Through Human Drugs". Food and Drug Administration. 2005. http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/WhatWeDo/UCM078941.pdf.
- ^ Angel, Marcia (7 December 2004). "Excess in the pharmaceutical industry". Canadian Medical Association Journal 171 (12): 1451–3. doi:10.1503/cmaj.1041594. PMC 534578. PMID 15583183. http://www.cmaj.ca/cgi/content/full/171/12/1451#R5-12
- ^ "Correspondence: "Me-Too" Products – Friend or Foe?". The New England Journal of Medicine. 13 May 2004. http://www.nejm.org/doi/full/10.1056/NEJM200405133502019#t=article.
- ^ "Me too! Me too!". The Economist. 17 April 2007. http://www.economist.com/blogs/freeexchange/2007/04/me_too_me_too.
- ^ DiMasi, JA; Faden, LD (January 2011). "Competitiveness in follow-on drug R&D: a race or imitation?". Nat Rev Drug Discov. 10 (1): 23–27. doi:10.1038/nrd3296. PMID 21151030. http://www.nature.com/nrd/journal/v10/n1/full/nrd3296.html
- ^ Bhandari M, Busse JW, Jackowski D, Montori VM, Schunemann H, Sprague S, Mears D, Schemitsch EH, Heels-Ansdell D, Devereaux PJ (2004-02-17). "Association between industry funding and statistically significant pro-industry findings in medical and surgical randomized trials". http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=retrieve&db=pubmed&list_uids=14970094&dopt=Abstract. Retrieved 2007-05-24.
- ^ a b Moynihan R (2003-05- cvc31). Who pays for the pizza? Redefining the relationships between doctors and drug companies. 2: Disentanglement. BMJ: British Medical Journal. Volume 326, Issue 7400, Pages 1193–1196. Retrieved on 2007-10-06.
- ^ "Hogan & Hartson Update on Pharmaceutical Trial Registration" (PDF). 2008-03-03. http://www.hhlaw.com/files/Publication/edbf3429-125c-41c9-9442-b552e69b756c/Presentation/PublicationAttachment/972a9053-8c8d-46e4-ac96-ecf4892a8643/Pharma.pdf. Retrieved 2008-06-02.
- ^ Barnett, Antony (2003-12-07). "Revealed: how drug firms 'hoodwink' medical journals". London: The Observer. http://observer.guardian.co.uk/uk_news/story/0,6903,1101680,00.html. Retrieved 2007-05-24.
- ^ Sheldon, T (2002-05-25). "How whistleblowing cost one doctor £550000". BMJ (Clinical research ed.) 324 (7348): 1240. doi:10.1136/bmj.324.7348.1240. PMC 1123215. PMID 12028975. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1123215.
- ^ Lenzer, Jeanne (2005-05-27). "What Can We Learn from Medical Whistleblowers?". PLoS medicine 2 (7): e209. doi:10.1371/journal.pmed.0020209. PMC 1140678. PMID 15913416. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1140678.
- ^ Liberti L, McAuslane JN, Walker S (2011). "Standardizing the Benefit-Risk Assessment of New Medicines: Practical Applications of Frameworks for the Pharmaceutical Healthcare Professional". Pharm Med 25 (3): 139-46. http://adisonline.com/pharmaceuticalmedicine/Abstract/2011/25030/Standardizing_the_Benefit_Risk_Assessment_of_New.1.aspx.
- ^ "US Congress Warned of Gathering Storm at FDA". PharmaTimes. http://www.pharmatimes.com/WorldNews/article.aspx?id=12822. Retrieved 2008-02-08.
- ^ "Electronic Orange Book". U.S. Food and Drug Administration. http://www.fda.gov/cder/ob/default.htm. Retrieved 2007-05-31.
- ^ "The Orphan Drug Act (as amended)". U.S. Food and Drug Administration. http://www.fda.gov/orphan/oda.htm. Retrieved 2007-09-24.
- ^ Harris, Gardiner (2008-12-03). "British Balance Benefit vs. Cost of Latest Drugs". The New York Times. http://www.nytimes.com/2008/12/03/health/03nice.html?pagewanted=3&_r=1&incamp=article_popular_3. Retrieved 2010-05-22.
- ^ a b Herper, Matthew and Kang, Peter (2006-03-22). "The World's Ten Best-Selling Drugs". Forbes. http://www.forbes.com/home/sciencesandmedicine/2006/03/21/pfizer-merck-amgen-cx_mh_pk_0321topdrugs.html. Retrieved 2007-05-31.
- ^ "IMS Reports 11.5 Percent Dollar Growth in '03 U.S. Prescription Sales". IMS Health. 2004-02-17. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_3665_44771558,00.html. Retrieved 2007-06-01.
- ^  "Why We Pay So Much," TIME magazine, Feb. 2, 2004
- ^ "IMS Health Forecasts 5 to 6 Percent Growth for Global Pharmaceutical Market in 2007". IMS Health. 2006-10-24. http://www.imshealth.com/ims/portal/front/articleC/0,2777,6025_3665_79210022,00.html. Retrieved 2007-06-19.
- ^ "Prescription for change". Teradata Magazine online. March 2005. Archived from the original on 2007-09-28. http://web.archive.org/web/20070928024747/http://www.teradata.com/t/page/131951/. Retrieved 2007-06-19.
- ^ Top 50 Pharmaceutical Companies Charts & Lists, Med Ad News, September 2007
- ^ IMS Health 2008, Top 15 Global corporations
- ^ Frequently Asked Questions (FAQs)
- ^ "New Drug Approvals in 2006" (PDF). March 2007. Archived from the original on 2008-02-28. http://web.archive.org/web/20080228023631/http://www.phrma.org/files/NDA2006.pdf. Retrieved 2008-02-23.
- ^ "Assessment of Authorized Generics in the U.S" (PDF). IMS Consulting. June 2006. Archived from the original on 2008-02-28. http://web.archive.org/web/20080228023633/http://www.phrma.org/files/IMS+Authorized+Generics+Report_6-22-06.pdf. Retrieved 2008-02-23.
- ^ http://www.dddmag.com/news-Sanofi-Laying-Off-1700-in-US-101110.aspx
- ^ "The medicare Prescriptions Drug Benefit" (PDF). Kaiser Family Foundation. September 2005. Archived from the original on 2006-02-17. http://web.archive.org/web/20060217051127/http://www.kff.org/medicare/upload/7044-02.pdf. Retrieved 2007-06-12.
- ^ a b "ZS Associates; Pharmaceutical". http://www.zsassociates.com/news_events/news_media/the_doctor_wont_see_you_mr_pharma_rep_now/.
- ^ "No Free Lunch". http://www.nofreelunch.org/. Retrieved 2007-05-23.
- ^ Kaufman, Marc (2005-05-06). "Merck CEO Resigns as Drug Probe Continues". Washington Post. http://www.washingtonpost.com/wp-dyn/content/article/2005/05/05/AR2005050501115_pf.html. Retrieved 2007-05-23.
- ^ "Drug Lobby Second to None: How the pharmaceutical industry gets its way in Washington". publicintegrity.org. 2005-07-07. http://www.publicintegrity.org/rx/report.aspx?aid=723. Retrieved 2007-05-23.
- ^ Ray Moynihan (2003-05-31). Drug company sponsorship of education could be replaced at a fraction of its cost. BMJ: British Medical Journal, Volume 326, Issue 7400, Page 1163. Retrieved on 2007-10-07.
- ^ "Senators Who Weakened Drug Bill Got Millions From Industry," USA Today, May 10, 2007
- ^ Koerner BI (March/April, 2003), Dr. No Free Lunch. Mother Jones, Retrieved on 2007-10-06.
- ^ "A Collection of Articles on Disease Mongering". Public Library of Science. http://collections.plos.org/plosmedicine/diseasemongering-2006.php. Retrieved 2007-05-23.
- ^ "UK parliamentarians put the pharma industry under the spotlight". European Public Health Alliance. http://www.epha.org/a/1773. Retrieved 2007-05-23.
- ^ Buchkowsky SS, Jewesson PJ. (2004) Industry sponsorship and authorship of clinical trials over 20 years. Ann Pharmacother. 2004 Apr;38(4):579-85. PMID 14982982
- ^ Perlis RH, Perlis CS, Wu Y, Hwang C, Joseph M, Nierenberg AA. (2005) Industry sponsorship and financial conflict of interest in the reporting of clinical trials in psychiatry Am J Psychiatry. Oct;162(10):1957-60.
- ^ Tungaraza T, Poole R. (2007) Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry. 2007 Jul;191:82-3. PMID 17602130
- ^ Medical schools and journals fight drug industry influence
- ^ Healy D (2006) The Latest Mania: Selling Bipolar Disorder PLoS Med 3(4): e185.
- ^ Cosgrove, Lisa, Krimsky, Sheldon,Vijayaraghavan, Manisha, Schneider, Lisa,Financial Ties between DSM-IV Panel Members and the Pharmaceutical Industry
- ^ Sharfstein, SS. (2005) Big Pharma and American Psychiatry: The Good, the Bad, and the Ugly Psychiatric News August 19, 2005 Volume 40 Number 16
- ^ See for example: 't Hoen, Ellen. "TRIPS, Pharmaceutical Patents, and Access to Essential Medicines: A Long Way from Seattle to Doha". Chicago Journal of International Law, 27(43), 2002; Musungu, Sisule F., and Cecilia Oh. "The Use of Flexibilities in TRIPS by Developing Countries: Can They Provide Access to Medicines?" Commission on Intellectual Property Rights, Innovation and Public Health, The World Health Organization, 2005.
- ^ WTO. "The Doha Declaration on TRIPS and public health", 2001. Available online at http://www.wto.org/english/thewto_e/minist_e/min01_e/mindecl_trips_e.htm.
- ^ "Pharmaceutical Manufacturer's Association v. The President of South Africa (PMA)", 2002 (2) SA 674 (CC) (S. Africa).
- ^ Helfer, Laurence R. and Graeme W. Austin. "Human Rights and Intellectual Property: Mapping the Global Interface". Cambridge University Press: 2011, p. 145-148.
- ^ Stephens, Joe (2000-12-17). "As Drug Testing Spreads, Profits and Lives Hang in Balance". Washington Post. http://www.washingtonpost.com/ac2/wp-dyn/A11939-2000Dec15. Retrieved 2007-06-25.
- ^ "Nigerians to sue US drug company over meningitis treatment|Kovac, Carl". BMJ. 2001-09-15. http://bmj.bmjjournals.com/cgi/content/full/323/7313/592/b. Retrieved 2007-06-25.
- ^ Wise, Jacqui (2001-01-27). "Pfizer accused of testing new drug without ethical approval". BMJ. http://www.bmj.com/cgi/content/full/322/7280/194. Retrieved 2007-06-25.
- ^ "Dying For Drugs". channel4.com. http://www.channel4.com/health/microsites/D/dying_for_drugs/resources4.html. Retrieved 2007-06-25.
- ^ http://www.cartercenter.org/healthprograms/showdoc.asp?programID=2&submenu=healthprograms
- ^ Pfizer Will Donate Fluconazole to South Africa
- ^ www.corporatecitizenship.novartis.com Novartis corporate citizenship
- Coyne J. Lessons in conflict of interest: "The construction of the martyrdom of David Healy and the dilemma of bioethics." American Journal of Bioethics 5 (1): W3-W14, 2005.
- Greene, Jeremy A., and Scott H. Podolsky, "Keeping Modern in Medicine: Pharmaceutical Promotion and Physician Education in Postwar America," Bulletin of the History of Medicine, 83 (Summer 2009), 331–77
- Marcia Angell: The truth about the drug companies. Random House, New York, 2004, 305 S. ISBN 0-375-50846-5.
- Ajai R. Singh, Shakuntala A. Singh: "Medical practice and the pharmaceutical industry: and ever the duo shall meet", Mens Sana Monographs, 2007, 5(1). Retrieved 2011-03-27. ISBN 978-81-89753-14-6
Economics of the industry
- Merrill Goozner: The $800 million pill. University of California Press, Berkeley, 2004, 297 S. ISBN 0-520-23945-8.
Relationship between pharma and the medical profession
- Joanna Moncrieff, ""An Unholy Alliance? Psychiatry and the influence of the pharmaceutical industry", Spinwatch, 27 June 2006.
- Jaconelli T, ""The Pharmaceutical Industry and its Influence on Doctors and Medical Students", Lancet Student, 2008.
- Jerome P Kassirer, ""Extent And Implications Of The Academia-Industry Connection", Mens Sana Monographs, 2007, 5(1), p1-6. Retrieved 2011-03-27.
- Joel Lexchin, ""Of Money And Trust In Biomedical Care", Mens Sana Monographs, 2007, 5(1), p7-10. Retrieved 2011-03-27.
Relationship between pharma and consumers (general public)
- Ray Moynihan, Alan Cassels: Selling sickness: How the world's biggest pharmaceutical companies are turning us all into patients. Nation Books, New York, 2005.
- Carlson, Bruce (2008-08-01). "Pharma Outsourcing on Upward Trajectory". Genetic Engineering & Biotechnology News (Mary Ann Liebert) 28 (14): pp. 14. ISSN 1937-8661. http://www.genengnews.com/articles/chitem.aspx?aid=2547. Retrieved 2008-09-26
Pharmaceutical industry by country
Wikimedia Foundation. 2010.